Kaam Pharma Limited

POWER SEARCH PRICING

SOLUTIONS

kaam pharma limited Company Information

Company Number

04115929

Next Accounts

Sep 2025

Directors

Mukund Patel

Arvind Makadia

View All

Shareholders

mukund kacharalal patel & hital mukund patel

Group Structure

View All

Industry

Wholesale of pharmaceutical goods

Registered Address

9 westfield drive, kenton, harrow, middlesex, HA3 9EG

Website

www.kaampharma.co.uk

kaam pharma limited Estimated Valuation

£4.7m

Pomanda estimates the enterprise value of KAAM PHARMA LIMITED at £4.7m based on Net Assets of £2.5m and 1.92x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Kaam Pharma Limited is a live company located in harrow, HA3 9EG with a Companies House number of 04115929. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in November 2000, it's largest shareholder is mukund kacharalal patel & hital mukund patel with a 100% stake. Kaam Pharma Limited is a mature, mid sized company, Pomanda has estimated its turnover at £8.4m with low growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Kaam Pharma Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 6 areas for improvement. Company Health Check FAQs

Health Rating3out of 5

3 Strong

1 Regular

6 Weak

Size

annual sales of £8.4m, make it smaller than the average company (£24.5m)

Growth

3 year (CAGR) sales growth of 1%, show it is growing at a slower rate (5.3%)

EXPORT

Kaam Pharma Limited's latest turnover from December 2023 is estimated at £8.4 million and the company has net assets of £2.5 million. According to their latest financial statements, Kaam Pharma Limited has 9 employees and maintains cash reserves of 0 as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Turnover	8,415,427	7,730,091	7,281,420	8,089,330	7,446,198	2,307,942	2,547,886	1,829,935	2,366,400	2,728,806	1,849,120	1,993,783	1,769,373	1,746,912
Other Income Or Grants
Cost Of Sales	7,020,772	6,540,556	6,127,411	6,876,262	6,300,844	1,955,955	2,189,827	1,543,428	1,988,922	2,294,919	1,575,163	1,730,601	1,522,706	1,522,908
Gross Profit	1,394,655	1,189,536	1,154,009	1,213,069	1,145,353	351,987	358,059	286,507	377,478	433,887	273,957	263,181	246,667	224,004
Admin Expenses	1,302,284	956,029	1,177,924	1,007,279	1,092,715	134,459	-94,928	-161,144	-42,525	67,485	104,237	169,460	90,382	118,666	-117,362
Operating Profit	92,371	233,507	-23,915	205,790	52,638	217,528	452,987	447,651	420,003	366,402	169,720	93,721	156,285	105,338	117,362
Interest Payable
Interest Receivable					6,041	11,066	5,371	1,747	2,301	1,383	736	382	199	66	66
Pre-Tax Profit	92,371	233,507	-23,915	205,790	58,679	228,594	458,358	449,398	422,304	367,785	170,456	94,103	156,484	105,404	117,428
Tax	-23,093	-44,366		-39,100	-11,149	-43,433	-87,088	-89,879	-84,461	-77,235	-39,205	-22,585	-40,686	-29,513	-32,880
Profit After Tax	69,278	189,141	-23,915	166,690	47,530	185,161	371,270	359,518	337,843	290,550	131,251	71,518	115,798	75,891	84,548
Dividends Paid
Retained Profit	69,278	189,141	-23,915	166,690	47,530	185,161	371,270	359,518	337,843	290,550	131,251	71,518	115,798	75,891	84,548
Employee Costs	730,529	705,745	586,902	550,408	527,917	527,445	520,271	432,149	317,343	151,658	94,544	144,151	91,806	87,385
Number Of Employees	9	9	8	8	8	8	8	7	6	3	2	3	2	2
EBITDA*	92,371	233,507	-23,915	205,790	52,638	226,091	461,066	453,974	426,306	371,198	172,905	97,042	159,119	107,168	121,511

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Tangible Assets	17,517	27,392	43,728	36,300	13,350	20,750	20,815	12,457	12,586	16,904	3,561	5,736	7,180	5,052	6,219
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets	17,517	27,392	43,728	36,300	13,350	20,750	20,815	12,457	12,586	16,904	3,561	5,736	7,180	5,052	6,219
Stock & work in progress						266,979	180,508	292,865	215,128	209,436	129,129	173,236	78,864	79,029	59,620
Trade Debtors	3,327,593	3,114,745	2,934,206	3,131,434	2,836,617	806,450	994,428	672,606	840,522	803,738	538,531	568,823	547,236	512,073	381,298
Group Debtors
Misc Debtors	8,633	9,626	9,601	11,363	10,149		38,352	29,105
Cash						1,610,824	1,340,063	808,485	588,844	331,641	221,450	72,907	79,697		26,326
misc current assets
total current assets	3,336,226	3,124,371	2,943,807	3,142,797	2,846,766	2,684,253	2,553,351	1,803,061	1,644,494	1,344,815	889,110	814,966	705,797	591,102	467,244
total assets	3,353,743	3,151,763	2,987,535	3,179,097	2,860,116	2,705,003	2,574,166	1,815,518	1,657,080	1,361,719	892,671	820,702	712,977	596,154	473,463
Bank overdraft
Bank loan
Trade Creditors	869,582	728,283	770,656	938,009	767,253	524,624	466,371	225,174	549,650	592,132	413,634	472,916	436,709	435,684	388,884
Group/Directors Accounts						157,000	114,000
other short term finances
hp & lease commitments
other current liabilities							155,577	123,396
total current liabilities	869,582	728,283	770,656	938,009	767,253	681,624	735,948	348,570	549,650	592,132	413,634	472,916	436,709	435,684	388,884
loans
hp & lease commitments
Accruals and Deferred Income	12,089	20,686	3,226	3,520	21,985
other liabilities
provisions
total long term liabilities	12,089	20,686	3,226	3,520	21,985
total liabilities	881,671	748,969	773,882	941,529	789,238	681,624	735,948	348,570	549,650	592,132	413,634	472,916	436,709	435,684	388,884
net assets	2,472,072	2,402,794	2,213,653	2,237,568	2,070,878	2,023,379	1,838,218	1,466,948	1,107,430	769,587	479,037	347,786	276,268	160,470	84,579
total shareholders funds	2,472,072	2,402,794	2,213,653	2,237,568	2,070,878	2,023,379	1,838,218	1,466,948	1,107,430	769,587	479,037	347,786	276,268	160,470	84,579

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Operating Activities
Operating Profit	92,371	233,507	-23,915	205,790	52,638	217,528	452,987	447,651	420,003	366,402	169,720	93,721	156,285	105,338	117,362
Depreciation						8,563	8,079	6,323	6,303	4,796	3,185	3,321	2,834	1,830	4,149
Amortisation
Tax	-23,093	-44,366		-39,100	-11,149	-43,433	-87,088	-89,879	-84,461	-77,235	-39,205	-22,585	-40,686	-29,513	-32,880
Stock					-266,979	86,471	-112,357	77,737	5,692	80,307	-44,107	94,372	-165	19,409	59,620
Debtors	211,855	180,564	-198,990	296,031	2,040,316	-226,330	331,069	-138,811	36,784	265,207	-30,292	21,587	35,163	130,775	381,298
Creditors	141,299	-42,373	-167,353	170,756	242,629	58,253	241,197	-324,476	-42,482	178,498	-59,282	36,207	1,025	46,800	388,884
Accruals and Deferred Income	-8,597	17,460	-294	-18,465	21,985	-155,577	32,181	123,396
Deferred Taxes & Provisions
Cash flow from operations	-9,875	-16,336	7,428	22,950	-1,467,234	225,193	428,644	224,089	256,887	126,947	148,817	-5,295	84,460	-25,729	36,597
Investing Activities
capital expenditure	9,875	16,336	-7,428	-22,950	7,400	-8,498	-16,437	-6,194	-1,985	-18,139	-1,010	-1,877	-4,962	-663	-10,368
Change in Investments
cash flow from investments	9,875	16,336	-7,428	-22,950	7,400	-8,498	-16,437	-6,194	-1,985	-18,139	-1,010	-1,877	-4,962	-663	-10,368
Financing Activities
Bank loans
Group/Directors Accounts					-157,000	43,000	114,000
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue					-31										31
interest					6,041	11,066	5,371	1,747	2,301	1,383	736	382	199	66	66
cash flow from financing					-150,990	54,066	119,371	1,747	2,301	1,383	736	382	199	66	97
cash and cash equivalents
cash					-1,610,824	270,761	531,578	219,641	257,203	110,191	148,543	-6,790	79,697	-26,326	26,326
overdraft
change in cash					-1,610,824	270,761	531,578	219,641	257,203	110,191	148,543	-6,790	79,697	-26,326	26,326

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for kaam pharma limited. Get real-time insights into kaam pharma limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for kaam pharma limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in HA3 area or any other competitors across 12 key performance metrics.

KAAM PHARMA LIMITED group structure

Kaam Pharma Limited has no subsidiary companies.

Ultimate parent company

KAAM PHARMA LIMITED

04115929

KAAM PHARMA LIMITED Shareholders

mukund kacharalal patel & hital mukund patel

100%

Kaam Pharma Limited currently has 3 directors. The longest serving directors include Mr Mukund Patel (Nov 2000) and Mr Arvind Makadia (Jul 2002).

officer	country	age	start	end	role
Mr Mukund Patel		61 years	Nov 2000	-	Director
Mr Arvind Makadia	England	62 years	Jul 2002	-	Director
Mrs Hital Patel		53 years	Jan 2023	-	Director

P&L

December 2023

turnover

8.4m

+9%

operating profit

92.4k

gross margin

16.6%

+7.7%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

2.5m

+0.03%

total assets

3.4m

+0.06%

cash

net assets

Total assets minus all liabilities

Similar Companies

philip chapper & company limited

flamingo pharma (uk) ltd

riteaim limited

mensana pharma ltd.

3.5

britannia medical limited

company number

04115929

Type

Private limited with Share Capital

industry

46460 - Wholesale of pharmaceutical goods

incorporation date

November 2000

ultimate parent company

None

previous names

kaam limited (April 2003)

address

9 westfield drive, kenton, harrow, middlesex, HA3 9EG

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 1 charges/mortgages relating to kaam pharma limited. Currently there are 1 open charges and 0 have been satisfied in the past.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for KAAM PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.

kaam pharma limited Company Information

kaam pharma limited Estimated Valuation

kaam pharma limited Estimated Valuation

kaam pharma limited Estimated Valuation

Kaam Pharma Limited Overview

Kaam Pharma Limited Health Check

KAAM PHARMA LIMITED financials

kaam pharma limited Credit Report and Business Information

Kaam Pharma Limited Competitor Analysis

kaam pharma limited Ownership

kaam pharma limited directors

kaam pharma limited company details

kaam pharma limited Charges & Mortgages

kaam pharma limited Capital Raised & Share Issues BETA

kaam pharma limited Companies House Filings - See Documents